Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has been assigned an average recommendation of “Buy” from the ten analysts that are covering the stock. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $41.50.

A number of equities analysts have recently issued reports on the company. Needham & Company LLC assumed coverage on Alder Biopharmaceuticals in a research report on Monday, May 15th. They set a “buy” rating and a $36.00 price target on the stock. Aegis reissued a “buy” rating and set a $41.00 price target on shares of Alder Biopharmaceuticals in a research report on Tuesday, April 25th. Jefferies Group LLC reissued a “buy” rating and set a $43.00 price target on shares of Alder Biopharmaceuticals in a research report on Monday, April 17th. Finally, Zacks Investment Research raised Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, February 16th.

Shares of Alder Biopharmaceuticals (NASDAQ:ALDR) traded down 0.29% during mid-day trading on Tuesday, hitting $17.40. 514,235 shares of the stock were exchanged. The firm’s market cap is $877.13 million. The stock’s 50 day moving average is $19.96 and its 200 day moving average is $22.30. Alder Biopharmaceuticals has a 12 month low of $16.83 and a 12 month high of $36.48.

Alder Biopharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by $1.04. During the same period last year, the company earned ($0.76) earnings per share. Analysts expect that Alder Biopharmaceuticals will post ($6.44) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/05/23/alder-biopharmaceuticals-inc-aldr-given-consensus-rating-of-buy-by-analysts.html.

Large investors have recently modified their holdings of the stock. Redmile Group LLC increased its stake in shares of Alder Biopharmaceuticals by 107.5% in the first quarter. Redmile Group LLC now owns 1,909,886 shares of the biopharmaceutical company’s stock worth $39,726,000 after buying an additional 989,336 shares during the last quarter. Citadel Advisors LLC increased its stake in shares of Alder Biopharmaceuticals by 1,209.4% in the first quarter. Citadel Advisors LLC now owns 467,387 shares of the biopharmaceutical company’s stock worth $9,722,000 after buying an additional 431,691 shares during the last quarter. Perceptive Advisors LLC bought a new stake in shares of Alder Biopharmaceuticals during the fourth quarter worth $7,991,000. Janus Capital Management LLC increased its stake in shares of Alder Biopharmaceuticals by 8.1% in the fourth quarter. Janus Capital Management LLC now owns 4,937,041 shares of the biopharmaceutical company’s stock worth $102,704,000 after buying an additional 368,158 shares during the last quarter. Finally, Clough Capital Partners L P increased its stake in shares of Alder Biopharmaceuticals by 168.6% in the fourth quarter. Clough Capital Partners L P now owns 468,435 shares of the biopharmaceutical company’s stock worth $9,743,000 after buying an additional 294,035 shares during the last quarter.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

12 Month Chart for NASDAQ:ALDR

Receive News & Ratings for Alder Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.